The misperception that clinical trial data reflect long-term drug safety: Lessons learned from efalizumab's withdrawal

Archives of Dermatology

Volumn 145, Issue 9, 2009, Pages 1037-1039

  Nijsten, Tamar ^a   Spuls, Phyllis I ^b   Naldi, Luigi ^c   Stern, Robert S ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Centro Studi Gruppo Italiano di Studi Epidemiologici in Dermatologia   (Italy)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EFALIZUMAB; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR;

ASEPTIC MENINGITIS; CLINICAL TRIAL; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENCEPHALITIS; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HUMAN; LEUKOENCEPHALOPATHY; MYELITIS; NEUROPATHY; NOTE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS;

EID: 70349314922     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.188     Document Type: Note

References (17)

1. European Medicines Agency. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf. Accessed April 21, 2009.
2. Food and Drug Administration. Efalizumab (marketed as Raptiva) information . http://www.fda.gov/cder/drug/infopage/efalizumab/default.htm. Accessed April 21, 2009.
3. Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol. 2003;121(5):951-962.
4. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1-233.
5. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008;158(5):1107-1116.
6. Korman DB, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol. 2009;145(8):937-942.
7. Efalizumab: new drug: plaque psoriasis: too many unknowns. Prescrire Int. 2006;15(81):8-11.
8. Food and Drug Administration. FDA public health advisory updated safety information about Raptiva (efalizumab). http://www.fda.gov/Drugs/DrugSafety/ PublicHealthAdvisories/ucm110605.htm. Accessed July 1, 2009.
9. Food and Drug Administration. Efalizumab postmarketing commitments. http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm. Accessed April 21, 2009.
10. Food and Drug Administration. Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. September 9, 2003. http://www.fda.gov/ohrms/dockets/ ac/03/transcripts/3983T1.htm. Accessed April 21, 2009.
11. Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. Drug Saf. 2008;31(8):715-726. (Pubitemid 352019569)
12. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213(3):204-214. (Pubitemid 44567830)
13. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743-752.
14. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med. 1994;331(20):1350-1353. (Pubitemid 24347007)
15. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396. (Pubitemid 43752541)
16. Cobert B. The FDA Drug Safety Bill: how safe are our drugs? Expert Opin Drug Saf. 2008;7(4):343-346.
17. Stern RS, Nijsten T. Insuring rapid and robust safety assessment [published correction appears in J Invest Dermatol. 2004;123(4):805]. J Invest Dermatol. 2004;122(3):857-858.